E. Wehrenberg-Klee

A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma

Love Goyal, Daniel Francis Ditoro, Francesco Facchinetti, E Martin et autres

BACKGROUND: Fibroblast growth factor receptor (FGFR) inhibitors have significantly improved outcomes for patients with FGFR-altered cholangiocarcinoma, leading to their regulatory approval in multiple countries. As with many targeted therapies, however, acquired resistance limits their efficacy. A comprehensive, multimodal approach is crucial to …

us, fr, jp (code pays fourni par la source)

Abstract No. 140 Hepatic Arterial Infusion of the Class C TLR9 Agonist SD-101 in Pressure Enabled Regional Immuno-Oncology (PERIO) Phase 1 Trials for Liver Tumors

R. Sheth, J. Kuban, J. Weintraub, E. Wehrenberg-Klee et autres

us (code pays fourni par la source)

Abstract No. 543 90Y Selective Internal Radiation Therapy for Ocular Melanoma Metastatic to the Liver: Dosimetry and Response Assessment

J. Panagides, S. Ganguli, Ronald Arellano, Xueying Chen et autres

us (code pays fourni par la source)